AXIM Biotechnologies Entered into an Exclusive Commercial Agreement with Verséa Ophthalmics for Novel Ophthalmic Diagnostics Solutions
Shots:
- Verséa gets an exclusive commercial right to AXIM’s portfolio of PoC lab testing readers and three biomarker diagnostic tests specialized in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis
- AXIM’s biomarker tests i.e, Ocular Immunoglobulin E (IgE) test & Lactoferrin test are both FDA-cleared and have dedicated Medicare CPT codes while Verséa plans to launch both tests at AAO 2022 and AAOPT conferences
- The third test, a quantitative tear Matrix Metalloproteinase 9 (MMP-9) test measures the intensity of inflammation in dry eye patients & is expected to be available in the next 18-24mos.
Ref: Globenewswire Image: AXIM Biotechnologies
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
